Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...

Trump's Department of Commerce is looking into what it calls national security threats from overseas drug manufacturing, and ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Eli Lilly's stock wobbled Thursday after a looming ... become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Eli Lilly's (LLY) stock wobbled Thursday after ... become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded. This could complicate ...